NewAmsterdam Pharma develops obicetrapib, an oral pill for lowering LDL cholesterol in patients with cardiovascular disease or high cholesterol. NAMS reports earnings on Wed, Nov 4, 2026. Over the past 90 days StreetAlpha recorded 4 whale options trades in NAMS, 25% of them bullish and 75% bearish. In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 5 | RBC Capital | Target lowered | Buy | |
| Sep 8 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 6 | RBC Capital | Target lowered | Buy | |
| Jun 30 | RBC Capital | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in NAMS in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAMS is in one of them and how their past NAMS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NAMS in an article yet. Here's the latest on the wider market.
About NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma is a biopharmaceutical company based in Naarden, Netherlands. It is developing obicetrapib, a once-a-day oral pill for lowering LDL cholesterol in patients with cardiovascular disease or high cholesterol who do not reach their targets on statins alone. The drug can be taken on its own or combined with ezetimibe, another cholesterol-lowering pill. The company plans to sell it in the United States itself and has given Menarini the rights to market it in most of Europe.
- Headquarters
- Narrden, Netherlands